Stevanato Group S.p.A.

What they do

Stevanato Group operates through two segments: Biopharmaceutical and Diagnostic Solutions, which supplies glass and plastic primary packaging, drug delivery devices, and diagnostic consumables; and Engineering, which provides customized automated equipment and inspection systems for pharmaceutical manufacturing. The company serves biopharma and diagnostics customers across Europe, Middle East and Africa, the Americas, and Asia Pacific. With a long history in glass converting, Stevanato now emphasizes high-value solutions such as prefillable syringes and integrated device platforms.

Revenue drivers

• Biopharmaceutical and Diagnostic Solutions — The largest segment, generating revenue from sales of glass vials, syringes, cartridges, and plastic containers, as well as drug delivery devices and diagnostic components. It benefits from long-term customer contracts and growing demand for biologics and injectables.
• Engineering — This segment designs, manufactures, and services automated visual inspection and packaging lines for pharmaceutical production. Revenue is recognized over time or at a point in time, depending on contract terms, and serves both external customers and internal needs.
• High Value Solutions (within Biopharmaceutical) — Includes premium products such as prefillable syringes, safety devices, and on-body injectors that offer higher margins and address complex drug formulations. This line is a strategic focus for margin expansion.
• After-sales and services — Includes spare parts, technical support, and maintenance for engineering equipment and ongoing service agreements for biopharma products. It provides recurring revenue and strengthens customer relationships.

Recent performance

For the full year 2025, Stevanato Group reported revenue from the Biopharmaceutical and Diagnostic Solutions segment in Europe, Middle East and Africa, the Americas, and Asia Pacific, with contributions from both segments also reflected in inter-segment eliminations. The company continues to invest in expanding its high-value solutions capacity, as evidenced by ongoing capital expenditures and recent acquisitions. Specifically, in 2025, the company recorded revenues from the Engineering segment and from Biopharmaceutical and Diagnostic Solutions, with customer concentration in both. Financial results include depreciation and amortization, personnel expenses, and other costs, with a focus on operational efficiency.

Strategy

Stevanato Group's strategy centers on expanding its high-value solutions portfolio, particularly in biologics and injectables, to capture growing market demand. The company is investing in manufacturing capacity and technological capabilities, as indicated by ongoing capital expenditures and acquisitions like Balda Medical GmbH. It also aims to strengthen its Engineering segment by providing integrated solutions that combine equipment and consumables. Geographic expansion, especially in Asia Pacific and the Americas, remains a priority. Management emphasizes innovation in drug delivery devices and diagnostic products to drive long-term growth.

Risks

• Customer Concentration — A significant portion of revenue is derived from a limited number of large pharmaceutical and biotech customers, and the loss of one or more could materially affect results.
• Regulatory and Quality Compliance — Products are subject to stringent FDA, EMA, and other regulations; failure to comply could lead to recalls, fines, or delays in product approvals.
• Supply Chain and Raw Material Costs — Reliance on glass tubing, resins, and other raw materials exposes the company to price volatility and supply disruptions, impacting margins.
• Foreign Exchange and Interest Rate Fluctuations — With operations in multiple currencies, changes in exchange rates, particularly EUR/USD, and interest rate movements can adversely affect financial results.

Outlook

Management expects continued demand for drug containment and delivery solutions, driven by biologics and injectables. The company plans to ramp up capacity for high-value solutions and integrate recent acquisitions to enhance offerings. Focus remains on operational efficiency and cost management to offset inflationary pressures. Growth is anticipated in Asia Pacific and the Americas, supported by ongoing investments.